MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

TG Therapeutics Inc

Open

SectorHealthcare

39.32 -2.33

Overview

Share price change

24h

Current

Min

38.04

Max

40.14

Key metrics

By Trading Economics

Income

19M

23M

Sales

24M

108M

P/E

Sector Avg

262.867

63.778

EPS

0.15

Profit margin

21.566

Employees

338

EBITDA

17M

33M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+7.48% upside

Dividends

By Dow Jones

Next Earnings

30 Apr 2025

Market Stats

By TradingEconomics

Market Cap

1.4B

6.3B

Previous open

41.65

Previous close

39.32

News Sentiment

By Acuity

61%

39%

336 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

TG Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

19 Aug 2024, 20:01 UTC

Earnings

IBD 50 Stock TG Therapeutics Breaks Out Bullishly After 'Solid' Quarter -- IBD

Peer Comparison

Price change

TG Therapeutics Inc Forecast

Price Target

By TipRanks

7.48% upside

12 Months Forecast

Average 42.8 USD  7.48%

High 55 USD

Low 10 USD

Based on 6 Wall Street analysts offering 12 month price targets forTG Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

5

Buy

0

Hold

1

Sell

Technical Score

By Trading Central

39.43 / 42.8Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

336 / 386 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.